A rare case of idiopathic cholestasis: Clinical conundrums complicating enzalutamide therapy in metastatic prostate cancer

Current safety data affirms enzalutamide does not cause clinically significant liver dysfunction that warrant therapy cessation. Therefore, clinicians should not withhold potentially successful therapy merely for suspected hepatotoxicity or PnC.

Detalles Bibliográficos
Autores principales: Liu, Jun, Agyapong, George, Misra, Debashish, Taylor, C. Douglas, Hirsh, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878062/
https://www.ncbi.nlm.nih.gov/pubmed/31788253
http://dx.doi.org/10.1002/ccr3.2427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878062/
https://www.ncbi.nlm.nih.gov/pubmed/31788253
http://dx.doi.org/10.1002/ccr3.2427

Ejemplares similares